Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit

Rhea-AI Summary

Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) has announced its participation in the BMO Capital Markets' Oncology Summit on October 8, 2024, in New York, NY. The company's Chief Medical Officer, Dr. Dominic Smethurst, will be part of a panel discussion titled 'Capitalizing on Validated Mechanism in Oncology' at 1:30 pm ET.

Additionally, Dr. Smethurst and Yuval Cohen, Ph.D., the Chief Executive Officer of Corbus, will be available for one-on-one investor meetings during the event. Interested parties are advised to contact their BMO Capital Markets sales representative for registration details.

News Market Reaction

+0.66%

1 alert

+0.66% News Effect

On the day this news was published, CRBP gained 0.66%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NORWOOD, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the Company will participate in BMO Capital Markets’ Oncology Summit, to be held October 8, 2024 in New York, NY. Dr. Dominic Smethurst, MA MRCP, Chief Medical Officer of Corbus, will participate in a panel titled Capitalizing on Validated Mechanism in Oncology. Dr. Smethurst will also be joined by Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, to participate in one-on-one investor meetings.

Panel Title: Capitalizing on Validated Mechanism in Oncology
Date: Tuesday, October 8, 2024
Presentation Time: 1:30 pm ET

Please contact your BMO Capital Markets sales representative to register for the conference.

About Corbus
Corbus Pharmaceuticals Holdings, Inc. is an oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

INVESTOR CONTACT:

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
Sean.moran@corbuspharma.com

Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com

FAQ

When is Corbus Pharmaceuticals (CRBP) participating in the BMO Capital Markets' Oncology Summit?

Corbus Pharmaceuticals (CRBP) is participating in the BMO Capital Markets' Oncology Summit on October 8, 2024, in New York, NY.

Who from Corbus Pharmaceuticals (CRBP) will be speaking at the BMO Capital Markets' Oncology Summit?

Dr. Dominic Smethurst, Chief Medical Officer of Corbus Pharmaceuticals (CRBP), will be speaking on a panel at the BMO Capital Markets' Oncology Summit.

What is the title of the panel Corbus Pharmaceuticals (CRBP) is participating in at the BMO Capital Markets' Oncology Summit?

The panel title is 'Capitalizing on Validated Mechanism in Oncology' at the BMO Capital Markets' Oncology Summit.

What time is Corbus Pharmaceuticals' (CRBP) panel presentation at the BMO Capital Markets' Oncology Summit?

Corbus Pharmaceuticals' (CRBP) panel presentation is scheduled for 1:30 pm ET on October 8, 2024, at the BMO Capital Markets' Oncology Summit.

Will Corbus Pharmaceuticals (CRBP) be available for investor meetings at the BMO Capital Markets' Oncology Summit?

Yes, Dr. Dominic Smethurst and Yuval Cohen, Ph.D., CEO of Corbus Pharmaceuticals (CRBP), will be available for one-on-one investor meetings during the event.